Latest news
25 items- PRAtea Pharmaceuticals Appoints Arthur S. Kirsch to Board of DirectorsBOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui
- PROvid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 InhibitorsCollaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton's expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programsDevelopment to focus on serious disorders that have few-to-no therapeutic options, including cerebral cavernous malformations and conditions presenting with seizuresOvid to invest $10 million in preferred equity in Graviton and will fund development programsTransaction has no milestone payments and Graviton is eligible for tiered double-digit royalties on commercial sales NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -
- SECSEC Form 15-12B filed by Kadmon Holdings, Inc.15-12B - Kadmon Holdings, Inc. (0001557142) (Filer)
- SECSEC Form EFFECT filed by Kadmon Holdings, Inc.EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)
- SECSEC Form EFFECT filed by Kadmon Holdings, Inc.EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)
- INSIDERSEC Form 4: Flowers Cynthia Louise gifted 20,150 shares and returned $103,075 worth of shares to the company (10,850 units at $9.50), closing all direct ownership in the company4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
- INSIDERSEC Form 4 filed by Cohen David E4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
- INSIDERSEC Form 4 filed by Ryan John L4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
- INSIDERSEC Form 4: Waksal Harlan returned $1,690,478 worth of shares to the company (177,945 units at $9.50), closing all direct ownership in the company4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
- INSIDERSEC Form 4: Moss Gregory S. returned $167,874 worth of shares to the company (17,671 units at $9.50), closing all direct ownership in the company4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
- INSIDERSEC Form 4 filed by Miller-Rich Nancy4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
- INSIDERSEC Form 4: Kirsch Arthur S returned $285,000 worth of shares to the company (30,000 units at $9.50), closing all direct ownership in the company4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
- INSIDERSEC Form 4: Bauer Eugene returned $63,802 worth of shares to the company (6,716 units at $9.50), closing all direct ownership in the company4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
- INSIDERSEC Form 4 filed by Konidaris Tasos4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
- INSIDERSEC Form 4: Meehan Steven returned $236,636 worth of shares to the company (24,909 units at $9.50), closing all direct ownership in the company4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
- INSIDERSEC Form 4: Carver Kyle returned $146,490 worth of shares to the company (15,420 units at $9.50), closing all direct ownership in the company4 - Kadmon Holdings, Inc. (0001557142) (Issuer)
- SECSEC Form POS AM filed by Kadmon Holdings, Inc.POS AM - Kadmon Holdings, Inc. (0001557142) (Filer)
- SECSEC Form S-8 POS filed by Kadmon Holdings, Inc.S-8 POS - Kadmon Holdings, Inc. (0001557142) (Filer)
- SECSEC Form S-8 POS filed by Kadmon Holdings, Inc.S-8 POS - Kadmon Holdings, Inc. (0001557142) (Filer)
- SECKadmon Holdings, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Events That Accelerate or Increase a Direct Financial Obligation, Other Events, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Kadmon Holdings, Inc. (0001557142) (Filer)
- SECSEC Form S-8 POS filed by Kadmon Holdings, Inc.S-8 POS - Kadmon Holdings, Inc. (0001557142) (Filer)
- SECSEC Form POS AM filed by Kadmon Holdings, Inc.POS AM - Kadmon Holdings, Inc. (0001557142) (Filer)
- SECSEC Form S-8 POS filed by Kadmon Holdings, Inc.S-8 POS - Kadmon Holdings, Inc. (0001557142) (Filer)
- SECSEC Form 25-NSE filed by Kadmon Holdings, Inc.25-NSE - Kadmon Holdings, Inc. (0001557142) (Subject)
- SECKadmon Holdings, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Kadmon Holdings, Inc. (0001557142) (Filer)
KDMN FAQ
7 questionsWhat does Kadmon Holdings, Inc. do?
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment...Where does KDMN stock trade?
Kadmon Holdings, Inc. (KDMN) is listed on NYSE.What sector and industry is KDMN in?
Kadmon Holdings, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Kadmon Holdings, Inc. go public?
Kadmon Holdings, Inc. (KDMN) completed its IPO in 2016.What are analysts saying about KDMN?
Kadmon Holdings, Inc. has had 3 recent analyst actions on file. The most recent action was from Mizuho: Neutral with a $950.00 price target on 2021-09-14. Recent price targets range from $900.00 to $950.00.What companies are similar to KDMN?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.), KIN (Kindred Biosciences, Inc.). Compare KDMN side-by-side with any of them on Quantisnow.How can I track KDMN on Quantisnow?
Quantisnow aggregates Kadmon Holdings, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KDMN to receive live email and push alerts on every new disclosure.